Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,125.79 -13.47 -0.43%
FTSE 100 6,579.58 -4.59 -0.07%
DAX 9,299.84 -17.98 -0.19%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Algeta schedules fourth quarter and full year 2012 results presentation, webcast and conference call


Algeta schedules fourth quarter and full year 2012 results presentation, webcast and conference call

OSLO, NORWAY -- (Marketwire) -- 02/18/13 -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its fourth quarter and full year 2012 results on Thursday, 28 February 2013. A presentation by Algeta's senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET. The presentation will also be webcast live and can be accessed through www.algeta.com where questions can also be submitted during the presentation.

The presentation will take place at 10:00 CET at:

Shippingklubben

Haakon VIIs gate 1

0161 Oslo

Norway.

Algeta's senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).

To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

US: +1 877 423 0830

UK: +44 20 7153 9154

Norway: +47 21 06 61 13

Sweden: +46 8-506 443 86

Denmark: +45 32 71 42 62

Switzerland: +41 44 580 65 22

Participant pin code: 434633#

To access the replay, please dial:

US: +1 877 679 2989

UK: +44 20 3364 5196

Norway: +47 23 50 02 03

Sweden: +46 8-505 564 73

Conference reference: 345360#

A replay version of the conference call will also be available at www.algeta.com.

The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

Press release:

http://hugin.info/134655/R/1678620/547936.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they ar e solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1678620]

For further information, please contact:

Mike Booth / Renate Birkeli +47 23 00 67 32

Communications & Corporate Affairs ir@algeta.com

Media enquiries: Mark Swallow +44 207 638 9571

Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk

Knut Ekern +47 22 04 82 00

Gambit Hill & Knowlton knut.ekern@hkstrategies.com

Kari Watson +1 781 235 3060

MacDougall Biomedical Communications kwatson@macbiocom.com

US investor enquiries:

Tricia Swanson +1 646 378 2953

The Trout Group tswanson@troutgroup.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement